フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
Guilford Pharmaceuticals Announces Phase III AQUAVAN(R) Trial Meets Primary Endpoint BALTIMORE, March 24 /PRNewswire-FirstCall/ -- Guilford...
Guilford Pharmaceuticals: AGGRASTAT(R) Injection Clinical Data Presented at American College of Cardiology Annual Meeting BALTIMORE, March 8...
Guilford Pharmaceuticals Reports 2004 Year-End Financial Results BALTIMORE, March 1 /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals...
Guilford Pharmaceuticals to Announce 2004 Year-End Financial Results on Tuesday, March 1, 2005 BALTIMORE, Feb. 10 /PRNewswire-FirstCall/...
Guilford Pharmaceuticals Completes Sale and Leaseback and Receives $19.4 Million in Net Proceeds BALTIMORE, Dec. 17 /PRNewswire-FirstCall/...
Guilford Pharmaceuticals to Acquire ProQuest Pharmaceuticals; Guilford to Obtain Exclusive Worldwide Ownership of AQUAVAN(R) Prodrug Technology...
Guilford Pharmaceuticals Presents New GLIADEL(R) Wafer Data at the Society for Neuro-Oncology Annual Meeting BALTIMORE, Nov. 22...
Guilford Pharmaceuticals Announces Equity Compensation Arrangement With Dean J. Mitchell Pursuant to NASDAQ Rules BALTIMORE, Nov. 17...
Dean J. Mitchell Appointed President and Chief Executive Officer of Guilford Pharmaceuticals BALTIMORE, Nov. 17 /PRNewswire-FirstCall/...
AGGRASTAT(R) Strategy Trial Data Presented At American Heart Association Annual Meeting Guilford's Phase III Development Plan Progresses;...
Guilford Pharmaceuticals Reports 2004 Third Quarter Results BALTIMORE, Nov. 8 /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals...
Guilford Pharmaceuticals to Announce Third Quarter 2004 Financial Results on Monday, November 8, 2004 BALTIMORE, Nov. 5 /PRNewswire-FirstCall/...
Guilford Pharmaceuticals Announces Orphan Drug Designation for GLIADEL(R) Wafer; Market Exclusivity for GLIADEL(R) Extends Until 2010 BALTIMORE...
Guilford to Present at UBS Global Life Sciences Conference BALTIMORE, Sept. 22 /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約